Sawai’s Missed Revenue Expectations Leave Analysts Lukewarm Despite Broader Optimism

Favorable Trends Seen In Sawai’s Gross Margins

After a transformative last fiscal year, Sawai presented its financial first quarter results for its 2025 year, with slight disappointment among analysts due to missed revenue forecasts.

Small Japanese flag amid generic pills
• Source: Shutterstock

Sawai Pharmaceuticals’ first quarter results were met with a slightly lukewarm reception from industry analysts due to missed revenue expectations.

The Japanese pharmaceutical giant reported a 2.7% growth in revenue to ¥44.3bn ($304.8m) compared to the first quarter of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business